Scholarlink

<p>Laryngeal squamous cell carcinoma (LSCC) presents significant treatment challenges, especially regarding recurrence after larynx-preservation therapy. We identified distinct microbial community structures between recurrence and non-recurrence groups, particularly highlighting the genera abundance of <i>Fusobacterium</i> and <i>Serratia</i>. However, larynx-preserving therapy did not significantly alter microbial diversity in recurrent patients. Survival analysis identified <i>Fusobacterium</i> and <i>Serratia</i> as independent prognostic factors for recurrence, leading to the development of a <i>Serratia-Fusobacterium</i> (SF) prognostic scoring model. The SF model achieved an AUC of 81.37% for predicting recurrence, outperforming the TNM staging system. LSCC patients classified as high-risk by the SF model exhibited significantly shorter disease-free survival (DFS) compared to low-risk patients in the LSCC cohort. Furthermore, the SF model demonstrated an AUC of 78.48% in the multi-center cohort for predicting recurrence. In conclusion, the <i>Serratia-Fusobacterium</i> prognostic scoring model can predict LSCC recurrence after larynx-preserving therapy and provide valuable insights to inform recommendations for LSCC surveillance.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating the prognostic value of microbial communities in predicting recurrence of laryngeal carcinoma: a multicenter case-control study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月10日

查看全文
  • Chi-Yao Hsueh,
  • Xiaohui Yuan,
  • Huiying Huang,
  • Yujie Shen,
  • Qiang Huang,
  • Weida Dong,
  • Danhui Li,
  • Hui-Ching Lau,
  • Xinhui Mao,
  • Simin Liang,
  • Lei Tao,
  • Ming Zhang,
  • Ji Sun,
  • Hongli Gong

摘要

Laryngeal squamous cell carcinoma (LSCC) presents significant treatment challenges, especially regarding recurrence after larynx-preservation therapy. We identified distinct microbial community structures between recurrence and non-recurrence groups, particularly highlighting the genera abundance of Fusobacterium and Serratia. However, larynx-preserving therapy did not significantly alter microbial diversity in recurrent patients. Survival analysis identified Fusobacterium and Serratia as independent prognostic factors for recurrence, leading to the development of a Serratia-Fusobacterium (SF) prognostic scoring model. The SF model achieved an AUC of 81.37% for predicting recurrence, outperforming the TNM staging system. LSCC patients classified as high-risk by the SF model exhibited significantly shorter disease-free survival (DFS) compared to low-risk patients in the LSCC cohort. Furthermore, the SF model demonstrated an AUC of 78.48% in the multi-center cohort for predicting recurrence. In conclusion, the Serratia-Fusobacterium prognostic scoring model can predict LSCC recurrence after larynx-preserving therapy and provide valuable insights to inform recommendations for LSCC surveillance.